An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is ...

When interferon treatment was being developed in the Soviet Union, this was effectively overlooked in the West during the cold-war era due to its concentration on the development of vaccines.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Recent insights reveal the potential role of interferon (IFN ... osteogenic differentiation offer a new perspective on the treatment of OPLL. By targeting the type I IFN pathway, it may be ...

Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

IFN-α2 induces sustained major or complete molecular remissions in a subset of PV patients with normalization of the bone marrow after long-term treatment (>60 months). These remissions ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein ...

St. Jude researchers identified a protein, voltage-dependent anion channel 2 (VDAC2), that tumors use as a “signal jammer” to prevent cancer cell death and evade the immune system’s functioning.